HIV Market To Meet Patent Cliff In 2026-27 But Novel Products Coming
Two-Drug Regimens Make Headway
Market Snapshot: Gilead’s Biktarvy and ViiV’s two-drug regimens are expected to dominate the HIV market over the next few years as market exclusivity losses loom, but drugs with new mechanisms of action, and longer-acting products, might influence market dynamics.
